Sulperazon for the Treatment of Severe and Nosocomial Infections
Authors:
I. Herold 1; I. Chytra 2; B. Horová 3
Authors‘ workplace:
ARO, Klaudiánova nemocnice, Mladá Boleslav, primář MUDr. Ivan Herold, CSc. 2 ARK FN Plzeň, přednosta doc. MUDr. Eduard Kasal, CSc. 3 Oddělení klinické mikrobiologie, FN Na Bulovce, Praha, primářka MUDr. Blanka Horová
1
Published in:
Anest. intenziv. Med., , 2002, č. 4, s. 175-183
Category:
Overview
The multicenter observational clinical trial evaluating clinical efficacy of Sulperazon (cefoperazone with sulbactam)followed 203 patients withsevere and nosocomial infectious complications.Majority of the patients were admitted to the intensive care unit (79.8%).The therapy was successfulin 80.3%with maximum efficacy in abdominal infections (91.9%).The lowest treatment efficacy was noted in the patients with sepsis (72.5%)andbronchopneumonia (76.4%).The most frequent treatment regime was 2x2 g i.v.in 24 hours for 10 days (median).The adverse effects were not in anycase indication for the interruption of the treatment.Ventilatory support,pneumonia,incorrect initial choice of antibiotic and higher number of givenantibiotics were significant risk factors for the failure of antibiotic therapy.Sulperazon was assessed as well tolerated antibiotics with excellent clinicalefficacy mainly in abdominal infections with negligible adverse effects.
Key words:
Sulperazon –treatment success –treatment failure
Labels
Anaesthesiology, Resuscitation and Inten Intensive Care MedicineArticle was published in
Anaesthesiology and Intensive Care Medicine
2002 Issue 4
Most read in this issue
- Pressure-volume Curve:Automated Measurement of Respiratory Mechanics –A.R.M.Software
- Haemodynamics in Organ Donors
- Initial Antibiotic Therapy of Bacterial Diseases at Patients in Intensive Care Units
- Cis-atracurium in Clinical Practice:Evaluation of Intubation Conditions,Haemodynamic Changes and Side Effects